Brian Hill
Director, Lymphoid Malignancies Program
Cleveland Clinic · Cleveland, United States
Leads the lymphoid malignancies program at Cleveland Clinic with expertise in MCL treatment optimization and clinical trials.
Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2.
Journal of hematology & oncology · Apr 27, 2026
Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy.
Blood cancer journal · Apr 25, 2026
Clinical strategies for lymphoma management: Recommendations from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Consensus Conference 2025.
Cancer · Apr 15, 2026
Correction: Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations.
Blood cancer journal · Apr 8, 2026
Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 cohort 3.
Blood · Mar 19, 2026
Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.
Blood advances · Feb 24, 2026
Integrative profiling strategies to guide personalized therapy in mantle cell lymphoma: a pilot study.
NPJ precision oncology · Nov 21, 2025
Author Correction: Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma.
Nature communications · Oct 7, 2024
Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving bendamustine-rituximab.
British journal of haematology · Jan 1, 2024